We are pleased to announce that our invested company Chemclin Diagnostics Co Ltd (the “Company”) completed its IPO on Shanghai Science & Innovation Board today.

The IPO price of the Company was set at RMB 7.15 per share and has made a remarkable closing price at RMB 24.94 per share with a 249% increment on the first trading day.

Chemclin is a leading PRC based In-Vitro Diagnostics (“IVD”) company with strong focus in the Chemiluminescence Immunoassay market. Leveraged by its IP-protected LiCA technology, the Company is specialized in research and development, production, sales and service of IVD products, including mainly selling IVD reagents to hospitals and clinical laboratories in China.

VMS has invested in the Company since February 2018. The Company achieved substantial business growth and technology innovation, including the development of a new generation LiCA platform and the launch of several new diagnostic reagents for various diseases in recent years.

Healthcare is one of the selected sectors that VMS focuses on. The team is led by Andrew Ng, Managing Director and Head of Healthcare of VMS Asset Management and comprises hybrid vigor and expertise in the Healthcare sector, exploring intrinsic value of distinctive investments within the sector. The investments in portfolio companies New Horizon Health (6606.HK), Pharmaron (300759.CH), KingMed (603882.CH), i-Mab (IMAB.US), Chemclin (688468.CH), CareRay (688607.CH) and Gamida Cell (GMDA.US) have already proven our commitment and we believe this diversity will seize more investment landscapes for our investors.

We look forward in the coming quarters with anticipation of a strong boost in our invested portfolio companies following Zhaoke’s upcoming IPO on the Hong Kong Stock Exchange.

If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.2021-04-09